StockData

Rani Therapeutics vs Tvardi Therapeutics

RANI and TVRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RANI and TVRD compare

Rani Therapeutics is the larger company, worth 4.7 times as much as Tvardi Therapeutics ($73.4M against $15.7M).

Tvardi Therapeutics scores higher on the StockData Score (6 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRANITVRD
Size and price
Market cap$73.4M$15.7M
Share price$0.526$1.18
Change, 1 year−75.2%−72.2%
Change, 5 years−98.5%−99.8%
Beta (5Y)0.851.11
Employees6912
StockData Score
Total score26 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S11.1×–
P/B2.2×1.0× (better)
FCF yield−31.7%–
Fair value$0.366–
Margin of safety−43.8%–
Growth
Revenue growth (TTM)449%–
Revenue growth, 5Y average28.7%–
Profitability
Operating margin−530%–
Net margin−493%–
FCF margin−353%–
Return on equity−249%−123% (better)
Return on invested capital−173%–
Financial health
Debt / equity–0.00
Interest coverage−71.9×–
Current ratio5.26 (better)2.86
Altman Z-score−1.36 (better)−9.66
Piotroski F-score5 (better)1
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions32.7%16.7%
Held by insiders30.6%15.6%
Insider net buying, 12 months$49.7K–
Short interest, % of float8.5%2.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.